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Abstract
Background: The relation of serum uric acid (SUA) with systemic inflammation has been little explored in humans and
results have been inconsistent. We analyzed the association between SUA and circulating levels of interleukin-6 (IL-6),
interleukin-1b (IL-1b), tumor necrosis factor- a (TNF-a) and C-reactive protein (CRP).
Methods and Findings: This cross-sectional population-based study conducted in Lausanne, Switzerland, included 6085
participants aged 35 to 75 years. SUA was measured using uricase-PAP method. Plasma TNF-a, IL-1b and IL-6 were
measured by a multiplexed particle-based flow cytometric assay and hs-CRP by an immunometric assay. The median levels
of SUA, IL-6, TNF-a, CRP and IL-1b were 355 mmol/L, 1.46 pg/mL, 3.04 pg/mL, 1.2 mg/L and 0.34 pg/mL in men and
262 mmol/L, 1.21 pg/mL, 2.74 pg/mL, 1.3 mg/L and 0.45 pg/mL in women, respectively. SUA correlated positively with IL-6,
TNF-a and CRP and negatively with IL-1b (Spearman r: 0.04, 0.07, 0.20 and 0.05 in men, and 0.09, 0.13, 0.30 and 0.07 in
women, respectively, P,0.05). In multivariable analyses, SUA was associated positively with CRP (b coefficient 6
SE = 0.3560.02, P,0.001), TNF-a (0.0860.02, P,0.001) and IL-6 (0.1060.03, P,0.001), and negatively with IL-1b
(20.0760.03, P = 0.027). Upon further adjustment for body mass index, these associations were substantially attenuated.
Conclusions: SUA was associated positively with IL-6, CRP and TNF-a and negatively with IL-1b, particularly in women.
These results suggest that uric acid contributes to systemic inflammation in humans and are in line with experimental data
showing that uric acid triggers sterile inflammation.
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Introduction
A high level of serum uric acid (SUA) was found to predict the
development of hypertension [1,2], obesity [3,4], insulin
resistance [3,5], kidney disease [2] and cardiovascular events
[2,6]. A potential mechanism by which uric acid (this
encompasses SUA and the extravascular effects of the urate
molecule) could be associated with cardiovascular morbidity is
via inflammation [7,8]. Experimental studies have demonstrated
that tissue damage releases endogenous substances including uric
acid which signals danger and stimulates inflammation [9]. SUA
has significant effect on vascular smooth muscle cells. It has been
shown that SUA when entering the vascular smooth muscle cell
stimulates the release of C-reactive protein (CRP) and chemokine
monocyte chemoattractant protein-1 (MCP-1), known to have a
major role in the initiation of atherosclerotic lesions [10–12].
Uric acid also stimulates human mononuclear cells to produce
interleukin 1b (IL-1b), interleukin 6 (IL-6) and tumor necrosis
factor a (TNF-a) [2].
Few studies have investigated the relationship between SUA
and systemic inflammation in humans. In small-sized studies
including patients with chronic heart failure, SUA was associated
positively with TNF- a [13,14] and IL-6 [13]. In two population-
based studies including 566 [15] and 1703 [16] healthy people,
SUA was associated positively with CRP. SUA was positively
associated with IL-6, TNF- a and CRP in 957 elderly people in
Italy [17] and SUA predicted CRP increase during follow-up [18].
By contrast, SUA was not associated with IL-6, TNF- a and CRP
in 333 elderly men in Taiwan [19].
Given the paucity of data from large-scale population-based
studies and the inconsistent results obtained so far, we explored the
associations of SUA with circulating levels of IL-6, IL-1b, TNF-a
and CRP and assessed whether sex modified these associations in
the CoLaus study.
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Methods
Study population
The Colaus study is a cross-sectional population-based study
conducted in Lausanne, Switzerland. Details of the study have
been previously described [20]. Briefly, a simple, non-stratified
random sampling of 19,830 participants, corresponding to 35% of
the source population, was drawn, of which eventually 6184
participants were included. Inclusion criteria included a written
informed consent, age between 35–75 years and being of
Caucasian origin. The study was approved by Ethics Committee
of the University of Lausanne. Recruitment began in June 2003
and ended in May 2006.
Study procedure and measurements
Participants attended the outpatient clinic at the Centre
Hospitalier Universitaire Vaudois (CHUV) in the morning after
an overnight fast. They were asked to continue taking their
medications as usual. This examination included a detailed health
questionnaire, physical examination with anthropometric measures
by trained and certified field interviewers and laboratory testing. In
this analysis, smoking was defined as present if the participant
reported to be current smoker at the time of examination and
alcohol consumption was defined as present for participants who
reported drinking alcohol at least once a day. Diuretic use was
assessed by recording all the prescribed drugs taken by the
participants and was considered as present if participants were
using drugs belonging to any class of diuretics. Body mass index
(BMI) was defined as weight divided by height in meter squared.
Overweight was defined as BMI equal to or more than 25 kg/m2
and obesity as BMI greater than 30 kg/m2. Blood pressure was
measured three times on the left arm using a clinically validated
automatic oscillometric device (Omron HEM-907, Matsusaka,
Japan) after applying the appropriate cuff size and after a period of
10 minutes rest with the subject in the sitting position. The average
of the second and third values was used for analysis. Hypertension
was defined as mean systolic blood pressure of $140 mmHg or
mean diastolic blood pressure of $90 mmHg or presence of anti-
hypertensive medication. A diagnosis of diabetes was made if fasting
plasma glucose was greater than or equal to 7.0 mmol/l or presence
of oral hypoglycaemic or insulin treatment.
Venous blood samples were collected after an overnight fasting.
Most clinical assays were performed by the CHUV Clinical
Laboratory on fresh blood samples whereas Pathway Diagnostics
(Los Angeles, CA) measured insulin. Glucose was measured by
glucose dehydrogenase (2.1% - 1.0% maximum inter and intra-
batch coefficients of variation); serum and urinary creatinine by
Jaffe kinetic compensated method (2.9% - 0.7%) and uric acid by
uricase-PAP (1.0% - 0.5%). Glomerular filtration rate (GFR) was
estimated using the abbreviated Modification of the Diet in Renal
Disease (MDRD) formula: 1866(serum creatinine [mmol/L]/88.4)
(21.154)6age (20.203)6F, where F= 1 for men and F= 0.742 for
women [21].
Cytokine levels were measured using a multiplexed particle-
based flow cytometric cytokine assay [22], a methodology used in
other studies [23]. Milliplex kits were purchased from Millipore
(Zug, Switzerland). The procedures closely followed the manufac-
turer’s instructions. The analysis was conducted using a conven-
tional flow cytometer (FC500 MPL, Beckman Coulter, Nyon,
Switzerland). Lower detection limits for IL-1b, IL-6 and TNF-a
were 0.2 pg/ml. Intra and inter-assay coefficients of variation were
15% and 16.7% for IL-1b, 16.9% and 16.1% for Il-6 and 12.5%
and 13.5% for TNF-a, respectively. For quality control, repeated
measurements were conducted for 80 subjects randomly drawn
from the initial sample. High sensitive CRP (CRP) was assessed by
immunoassay and latex HS (IMMULITE 1000–High, Diagnostic
Products Corporation, LA, CA, USA) with maximum intra- and
interbatch coefficients of variation of 1.3% and 4.6%, respectively.
Statistical analysis
Because SUA levels strongly differ by sex, men and women were
analyzed separately. Continuous variables were summarized as
mean6 standard deviation (SD) or as median and interquartile
range [IQR] while categorical variables as number of subjects and
percentages. We used t-test or Wilcoxon ranksum test and chi-
square test to compare the differences in distribution of continuous
and categorical covariates, respectively, between men and women.
All values of IL-1b, IL-6 and TNF-a below the detection level
(0.2 pg/ml), were substituted with a value (0.133) equivalent to
two-thirds of the lower detection limit as recommended by
Hornung et al [24] . Spearman’s rank correlation test was used to
analyze the association of SUA with inflammatory cytokines and
Fischer’s Z transformation to compare the correlation coefficients
between men and women. We plotted the distribution of the
inflammatory cytokines across sex-specific SUA quintiles and used
a non-parametric test to assess for trends across the sex-specific
SUA quintiles. These quintiles were generated separately in men
and women, which leads to an equal proportion of men and
women across quintiles. The distribution of unadjusted and
adjusted beta-coefficients of log-transformed inflammatory mar-
kers across sex-specific SUA quintiles was performed using a linear
regression. The P-value for trend was obtained by a test of
‘departure from linear trend’ using a likelihood ratio test (LRT)
comparing a model assuming a linear trend for SUA with another
estimating separate effects for each SUA quintiles. We considered
the P-value obtained from a linear model as the value for P-trend
whenever the LRT showed no difference in the fit of the two
models. In the adjusted models, we controlled for only those co-
variates that were both associated with SUA and inflammatory
markers in our data; hence age, sex, BMI, alcohol intake, smoking,
GFR, diabetes, hypertension and use of diuretics were included.
We examined the association of SUA (independent variable of
interest) with log-transformed values of inflammatory markers as
the dependant variable, one at a time using linear regression
models. We started by univariate analysis and subsequently fitted
models adjusting for (1) age, (2) age and BMI, (3) age, BMI,
alcohol intake, smoking, GFR, diabetes, hypertension and use of
diuretics. To assess if the relation was modified by gender, we
included a multiplicative interaction parameter between sex and
SUA into the linear models. We also performed the univariate and
multivariable analysis after excluding values that were below the
lower detection limit. We conducted sensitivity analysis excluding:
(1) diabetic subjects (n = 401) (2) hypertensive subjects (n = 2223),
(3) subjects treated with drugs that potentially influence SUA levels
(including acetylsalicylic acid, diuretics, angiotensin converting
enzymes inhibitors , angiotensin receptor blockers and other drugs
known to induce hyperuricemia and hypouricemia) (n = 1168) and
(4) subjects with cardiovascular diseases (CVD) (n = 246). We also
conducted stratified analyses by overweight status and alcohol
consumption (non-drinkers vs regular alcohol drinkers). The
significance level used for two-sided tests was P,0.05. All tests
were performed using Stata 11.0 (StataCorp, College Station, TX,
USA).
Results
Among the 6184 participants, 47% were men. The proportion
of missing data ranged from 0.03% to 2% (for interleukins and
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TNF-a). The proportion of values that were below the lower limit
of detection of the laboratory assays was 37.5%, 7.3% and 0.6%
for IL-1b, IL-6 and TNF-a, respectively.
The main demographic and clinical characteristics of the
Colaus population according to sex are presented in Table 1.
SUA was significantly higher in men (361675.7) than in women
(270.6667.2) as well as the prevalences of reported alcohol
consumption and smoking. Men had higher BMI and fasting
plasma glucose than women. The overall prevalences of diabetes
and hypertension in the study population were 6% and 36%,
respectively, with higher prevalences in men. A small proportion
of participants (2.3%) were on diuretics and 16.6% were on other
drugs (acetylsalicylic acid, ACE inhibitors, allopurinol and
angiotensin receptor blockers) known to potentially influence
SUA levels.
Of the initial 6184 participants, 6085 (98.4%) had serum
cytokines assessed. Table 2 describes the correlations of the
different inflammatory cytokines with SUA separately for men and
women. With the exception of IL-1b which had an inverse
association with SUA, all markers showed a significant positive
correlation with SUA. The strongest correlation was observed
between SUA and CRP both in men (r = 0.20, p,0.001) and
women (r = 0.30, p,0.001). These correlations were significantly
stronger in women than in men for IL-6, TNF-a and CRP (p-
value for test of equality of the correlation coefficients being 0.032,
0.015 and ,0.001 respectively).
Figure 1 shows the median and the interquartile range of the
different inflammatory cytokines plotted across the sex-specific
quintiles of SUA separately in men and women. There was a
significant negative trend for IL-1b with the relationship being
stronger in women than in men (P-trend,0.001 in women vs. P-
trend= 0.010 in men); women also had higher median values in
almost all the quintile groups. Although IL-6 was showing a
positive trend, the relationship was not as obvious in men. Strong
significant positive trends (p,0.001) were observed for TNF-a and
CRP both in men and women. These results are also supported by
findings in Table 3 and 4 which present the beta coefficients
using the inflammatory cytokines as dependent and sex-specific
SUA quintiles as independent variable. On adjusting for important
co-variates, only CRP still showed strong positive trends in men
and women.
In the univariate analysis (Table 5), SUA was a strong
significant predictor of IL-1b, IL-6, TNF-a and CRP in women;
conversely, in men a strong significant association was evident only
for TNF-a and CRP. The beta coefficients for SUA were almost
twice as large in women as in men. Adjustment for age slightly
attenuated all the coefficients, whereas adding BMI as a covariate
in the multivariable models substantially reduced the size of the
beta coefficients for SUA, particularly in women and this
reduction was massive for CRP in both men and women. The
associations, however, still remained significant except for IL-6.
Further adjustment for alcohol intake, smoking, GFR, diabetes,
hypertension and use of diuretics, had little impact on the
Table 1. Characteristics of the Colaus sample.
Overall (n = 6,184) Male (n =2,933) Female (n=3251)
Mean SD/IQR Mean SD/IQR Mean SD/IQR p-value
Age (years) 53.1 10.8 52.6 10.8 53.5 10.7 ,0.001
Alcohol consumption, % 25.4 36.1 15.7 ,0.001
Current smoking, % 27 29.3 25 ,0.001
Diabetes, % 6.5 9.6 3.7 ,0.001
Hypertension, % 35.9 42.1 30.4 ,0.001
Diuretics use, % 2.3 1.7 2.8 0.003
BMI (kg/m2) 25.8 4.6 26.6 4 25.1 4.9 ,0.001
Serum uric acid (mmol/L) 313.5 84.5 361.1 75.7 270.6 67.2 ,0.001
Fasting glucose (mmol/l) 5.6 1.1 5.8 1.2 5.3 1 ,0.001
GFR (ml/min/1.73 m2) 83.6 16.6 86.7 17.4 80.7 15.2 ,0.001
IL-1b (pg/mL)* 0.4 0.1–1.7 1.5 0.7–3.5 1.2 0.5–2.9 ,0.001
IL-6(pg/mL)* 1.3 0.6–3.2 0.3 0.1–1.5 0.5 0.1–1.9 ,0.001
TNF-a (pg/mL)* 2.9 1.8–4.5 3 1.9–4.6 2.7 1.7–4.4 ,0.001
CRP (mg/L)* 1.3 0.6–2.7 1.2 0.6–2.6 1.3 0.6–2.9 0.013
BMI = body mass index; GFR = glomerular filtration rate (calculated according to Modification in Diet in Renal Disease equation); IL-1b= interleukin-1b; IL-6 = interleukin-
6: TNF-a= tumour necrosis factor-alpha; CRP = ultrasensitive C-reactive protein.
Results are presented as mean (SD), percentages or median (interquartile range) for those marked with an asterix. Between-group comparisons by ttest, Chi-square test
or Wilcoxon ranksum test.
doi:10.1371/journal.pone.0019901.t001
Table 2. Spearman’s correlation coefficient of inflammatory
markers with uric acid according to sex.
Male Female
r p-value r p-value P-value*
IL-1b 20.05 0.014 20.07 ,0.001 0.286
IL-6 0.04 0.036 0.09 ,0.001 0.032
TNF-a 0.07 ,0.001 0.13 ,0.001 0.015
CRP 0.20 ,0.001 0.30 ,0.001 0.000
IL-1b= interleukin-1b; IL-6 = interleukin-6: TNF-a= tumour necrosis factor-alpha;
CRP= ultrasensitive C-reactive protein.
*P-value testing the difference in correlation coefficient between men and
women.
doi:10.1371/journal.pone.0019901.t002
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associations. Removing values that were below the lower detection
limits led to very similar results. Similarly, sensitivity analysis
excluding diabetics, subjects on diuretics or with cardiovascular
disease did not substantially change the results and led to similar
conclusions. However, on excluding hypertensive subjects, SUA
was no longer associated with IL-6.
The associations of SUA with log-transformed inflammatory
cytokines were also present in normal-weight men and women for
TNF-a and CRP, but were not significant for IL-6 and IL-1b
(Table S1). In teetotalers, SUA was associated with all cytokines
in women but only with CRP in men (Table S1). These results
show that the reported associations between SUA and inflamma-
tory markers are not due to alcohol intake.
Discussion
In this population-based study of Caucasians aged 35 to 75
years, we found a strong positive association of SUA with CRP
and a weaker, albeit significant, positive association of SUA with
TNF-a and IL-6 in men and women, which was in part mediated
Figure 1. Distribution of inflammatory markers across sex-specific quintiles of serum uric acid by sex. Dots are median and bars are
interquartile range. Blue colour indicates men and red colour indicates women. Z and p values represent non-parametric test for trends across
quintiles. IL-1b= interleukin-1b; IL-6 = interleukin-6: TNF-a= tumour necrosis factor-alpha; CRP = ultrasensitive C-reactive protein; M=men;
W=women.
doi:10.1371/journal.pone.0019901.g001
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by BMI. These findings support the hypothesis that uric acid is
involved in sterile (i.e., non-infectious) inflammation by triggering
the release of inflammatory cytokines, in particular CRP and
TNF-a. Such systemic inflammation may eventually contribute to
the development of atherosclerosis, hypertension and diabetes.
These findings are in line with recent experimental data in mice
showing that uric acid represents a major proinflammatory
damage-associated molecular pattern (DAMP) [25].
To the best of our knowledge, this is the largest population-
based study to assess the relationship between SUA and
circulatory inflammatory cytokines. As compared to other
population-based studies such as the InCHIANTI study [17],
the Colaus population had lower mean age and fewer participants
suffered from diabetes, hypertension or cardiovascular diseases.
Hence, this study provides information on the relationship
between SUA and the different inflammatory cytokines in
relatively young and healthy individuals.
As in the InCHIANTI study [17], the findings from the present
study showed that SUA was positively associated with CRP.
Similar findings were also reported by Frohlich et al [16] and Saito
et al [15]. Indeed, in the present study, CRP remained strongly
significant even after adjustment for important potential con-
founders such as BMI. Although controversial, these finding are in
keeping with the theory that high uric acid may contribute to the
atherosclerotic process by stimulating the release of CRP, an
established marker of inflammation. In fact, in vitro studies support
this hypothesis; it has been shown that uric acid enters the vascular
smooth muscle cells, where it stimulates pro-inflammatory
response, leading to increased cell proliferation and production
of CRP and other inflammatory mediators [10,26].
SUA was positively and independently associated with TNF-a
in both men and women in the current study, confirming previous
findings from patients with chronic heart failure [13] and from the
InCHIANTI study [17]. These findings are consistent with
experimental data supporting the role of SUA in stimulating the
release of TNF-a. A marked increase in circulating TNF-a levels
has been observed on infusion of uric acid into mice [27]. More
recently, cell culture experiments by Bordoni et al [28] showed the
role of uric acid in signal transduction in the apoptotic pathway,
subsequently leading to inflammatory reaction. They also
demonstrated that uric acid stimulates the mononuclear cells to
produce TNF-a [28].
IL-6 is a major stimulus for production of most acute phase
proteins and plays an important role as a mediator of
inflammation [29]. In this study, we observed a positive and
significant association between SUA and IL-6 as long as it was not
adjusted for BMI, indicating that this relationship appears to be
largely dependent on BMI. The finding of a positive association
Table 3. Unadjusted and adjusted linear regression coefficients of sex-specific quintiles of uric acid (95% CI) on log of
inflammatory markers in males.
Q1 Q2 Q3 Q4 Q5 P-trend
Serum uric acid (mmol/L) 271.5 319 355 394 463
IL-1b (pg/mL) Unadjusted Ref 20.07 20.12 20.18 20.24 0.008
(20.27;0.11) (20.31;0.07) (20.37;0.01) (20.43;20.05)
Fully adjusted Ref 20.08 20.09 20.14 20.13 0.182
(20.27;0.11) (20.28;0.09) (20.33;0.06) (20.33;0.08)
Fully adjusted excluding BMI Ref 20.07 20.09 20.12 20.10 0.261
(20.26;0.12) (20.27;0.10) (20.31;0.07) (20.30;0.10)
IL-6(pg/mL) Unadjusted Ref 20.13 0.04 20.11 0.14 0.121
(20.30;0.03) (20.12;0.20) (20.28;0.05) (20.03;0.30)
Fully adjusted Ref 20.15 0.01 20.15 0.06 0.603
(20.32;0.01) (20.15;0.18) (20.32;0.02) (20.12;0.23)
Fully adjusted excluding BMI Ref 20.13 0.04 20.11 0.13 0.164
(20.30;0.03) (20.12;0.20) (20.27;0.06) (20.04;0.30)
TNF-a (pg/mL) Unadjusted Ref 20.01 0.07 20.01 0.18 0.002
(20.11;0.09) (20.03;0.17) (20.11;0.10) (0.08;0.28)
Fully adjusted Ref 20.02 0.05 20.04 0.12 0.088
(20.13;0.08) (20.05;0.15) (20.15;0.06) (0.01;0.23)
Fully adjusted excluding BMI Ref 20.02 0.06 20.02 0.15 0.014
(20.12;0.09) (20.04;0.16) (20.12;0.08) (0.05;0.26)
CRP (mg/L) Unadjusted Ref 0.21 0.28 0.35 0.66 ,0.001
(0.09;0.33) (0.16;0.39) (0.23;0.47) (0.55;0.78)
Fully adjusted Ref 0.15 0.20 0.22 0.41 ,0.001
(0.04;0.26) (0.09;0.31) (0.11;0.34) (0.29;0.53)
Fully adjusted excluding BMI Ref 0.21 0.28 0.36 0.62 ,0.001
(0.09;0.32) (0.17;0.40) (0.24;0.48) (0.50;0.74)
*median value of serum uric acid in each quintile. IL-1b= interleukin-1b; IL-6 = interleukin-6: TNF-a= tumour necrosis factor-alpha; CRP =ultrasensitive C-reactive protein.
Adjusted for age, alcohol intake, smoking, BMI, GFR (calculated according to Modification in Diet in Renal Disease equation), diabetes, hypertension & use of diuretics.
doi:10.1371/journal.pone.0019901.t003
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between SUA and IL-6 is also consistent with the finding from
patients with chronic heart failure [13] and from the InCHIANTI
study [17], but contrasts with a study on institutionalized elderly
men in Taiwan [19]. The positive findings are in agreement with
the finding that uric acid stimulates human mononuclear cells to
produce IL-6 [2].
A significant negative association of SUA with circulating IL-1b
levels was found in men and women. To the best of our
knowledge, the only study in human that assessed the relationships
between SUA and IL-1b found no association between the two
[13]; however, the sample size was limited to 39 patients with
chronic heart failure and 16 healthy controls. Considering the key
role of the IL-1 pathway in sterile inflammation with IL-1b acting
as a potent proinflammatory cytokine [30], the observation that
monosodium urate crystals stimulate IL-1 production by neutro-
phils [31], and the recent identification of uric acid as a
proinflammatory DAMP [25], the negative association of SUA
with IL-1b was unexpected and its interpretation is not
straightforward. First, the results of in vitro and in vivo experimental
data do not always translate to humans. This is, for instance, true
for SUA that is substantially higher in humans than in mice
because uricase is inactive in humans. Second, small amounts of
IL-1b are known to be sufficient to cause biological effects [30]
and current IL-1b assays may not be sensitive enough to capture
the whole spectrum of biologically relevant effects. Third, it is not
clear that circulating IL-1b levels are a good proxy for local IL-1b
activity in specific organs. There is also a feedback control on IL-
1b levels in chronic inflammation and what we are seeing is a
chronic state and not an acute reaction.
In addition, these results should be interpreted with caution
because, in the present study, 38% of the participants had IL-1b
below detection levels. Nevertheless, this value is, not unusual and
actually lower than reported elsewhere [32,33]. Interestingly,
analyses conducted after removing subjects with values below the
detection limit yielded very similar results. In the other study
reporting data on circulating IL-1b levels in humans, the issue of
undetectable values was not discussed [13], which limits
comparison. More sensitive assays are needed to better explore
and interpret the association of circulating IL-1b with SUA and
related cardiovascular traits.
Of interest, in the current study, the association between SUA
and inflammatory cytokines appeared to depend on BMI. It was
the addition of BMI into the models, and not so much of the other
co-variates, that attenuated the effect sizes. Obesity is associated
with increased SUA levels [3,34] and overproduction of
inflammatory molecules like TNF- a and IL-6 by the white
adipose tissue [35]. Yet, the nature, and direction, of the causal
link between hyperuricemia and obesity is unclear. Masuo et al
Table 4. Unadjusted and adjusted linear regression coefficients of sex-specific quintiles of uric acid (95% CI) on log of
inflammatory markers in females.
Q1 Q2 Q3 Q4 Q5 P-trend
Serum uric acid (mmol/L) 193 233 263 298 357
IL-1b (pg/mL) Unadjusted Ref 20.01 20.15 20.13 20.34 ,0.001
(20.19;0.17) (20.33;0.03) (20.31;0.05) (20.52;20.16)
Fully adjusted Ref 0.01 20.09 20.03 20.18 0.106
(20.17;0.19) (20.27;0.10) (20.21;0.16) (20.39;0.02)
Fully adjusted excluding BMI Ref 0.01 20.09 20.04 20.21 0.050
(20.17;0.19) (20.27;0.09) (20.22;0.15) (20.40;20.01)
IL-6(pg/mL) Unadjusted Ref 20.10 0.08 0.11 0.28 ,0.001
(20.26;0.06) (20.08;0.25) (20.05;0.27) (0.11;0.44)
Fully adjusted Ref 20.11 0.03 0.02 0.08 0.179
(20.28;0.05) (20.13;0.20) (20.15;0.19) (20.10;0.27)
Fully adjusted excluding BMI Ref 20.10 0.07 0.10 0.22 0.002
20.26;0.06) (20.09;0.24) (20.07;0.27) (0.04;0.39)
TNF-a (pg/mL) Unadjusted Ref 0.06 0.14 0.19 0.26 ,0.001
(20.04;0.16) (0.04;0.24) (0.08;0.29) (0.16;0.36)
Fully adjusted Ref 0.04 0.08 0.09 0.09 0.065
(20.06;0.14) (20.02;0.18) (20.01;0.20) (20.02;0.21)
Fully adjusted excluding BMI Ref 0.04 0.10 0.13 0.16 0.001
(20.06;0.14) (0.00;0.20) (0.03;0.23) (0.05;0.27)
CRP (mg/L) Unadjusted Ref 0.07 0.30 0.52 0.92 ,0.001
(20.04;0.19) (0.18;0.42) (0.40;0.64) (0.80;1.04)
Fully adjusted Ref 0.04 0.15 0.23 0.39 ,0.001
(20.07;0.15) (0.04;0.26) (0.11;0.34) (0.27;0.51)
Fully adjusted excluding BMI Ref 0.08 0.27 0.48 0.80 ,0.001
(20.03;0.20) (0.16;0.39) (0.36;0.60) (0.67;0.93)
*median value of serum uric acid in each quintile. IL-1b= interleukin-1b; IL-6 = interleukin-6: TNF-a= tumour necrosis factor-alpha; CRP =ultrasensitive C-reactive protein.
Adjusted for age, alcohol intake, smoking, BMI, GFR (calculated according to Modification in Diet in Renal Disease equation), diabetes, hypertension & use of diuretics.
doi:10.1371/journal.pone.0019901.t004
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showed that SUA predicts subsequent weight gain in nonobese,
healthy young men [36]. This is further substantiated by
experimental studies in animals which showed that allopurinol
prevents both fructose-induced hyperuricaemia and weight gain
[37]. Although these results could suggest that hyperuricemia
might cause obesity, one cannot differentiate, based on these
results, whether (1) hyperuricemia directly causes obesity or (2)
hyperuricemia and obesity share a common cause (e.g. fructose
intake). Hence, BMI may lie in the causal pathway linking SUA to
inflammatory markers and controlling for it may actually represent
an overadjustment, thus explaining the attenuation of the effect
sizes in the current study.
The strengths of this study are its population-based design, large
sample size, the availability of detailed information on major
confounders and the high quality of cytokine-dosing, resulting in
good reproducibility of results. The potential limitation is the
cross-sectional nature of the study which does not allow us to infer
causality and the relatively high number of undetectable values for
IL-1b, which may bias the results and limit the interpretation of
the results.
In conclusion, in this population-based sample, SUA was
positively associated with CRP, TNF-a and IL-6 in both men and
women suggesting that uric acid may have a role in inflammation
and subsequent inflammatory related diseases. The relation
between SUA and IL-1b merits further investigation. Our findings
may be clinically relevant in terms of primary prevention strategies
for chronic disease which may necessitate the need to consider
high SUA as a potential risk factor.
Supporting Information
Table S1 Fully adjusted models (excluding BMI) of uric acid and
log of inflammatory markers by BMI status and alcohol intake.
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Table 5. Linear Regression of serum uric acid (per 100 mmol/L) on log-transformed inflammatory markers, overall and by sex.
Overall Male Female P-value*
Univariate b-coeff S.E P-value b-coeff S.E P-value b-coeff S.E P-value
IL-1b (pg/mL) 20.14 0.03 ,0.001 20.10 0.04 0.015 20.19 0.04 ,0.001 0.061
IL-6 (pg/mL) 0.14 0.02 ,0.001 0.07 0.04 0.040 0.18 0.04 ,0.001 0.076
TNF-a (pg/mL) 0.1 0.01 ,0.001 0.08 0.02 ,0.001 0.15 0.02 ,0.001 0.030
CRP (mg/L) 0.26 0.02 ,0.001 0.30 0.03 ,0.001 0.51 0.03 ,0.001 ,0.001
Age & sex adjusted
IL-1b (pg/mL) 20.09 0.03 0.004 20.06 0.04 0.120 20.12 0.05 0.009 0.269
IL-6 (pg/mL) 0.1 0.03 ,0.001 0.05 0.04 0.161 0.17 0.04 ,0.001 0.156
TNF-a (pg/mL) 0.09 0.02 ,0.001 0.06 0.02 0.003 0.11 0.03 ,0.001 0.128
CRP (mg/L) 0.34 0.02 ,0.001 0.26 0.03 ,0.001 0.46 0.03 ,0.001 ,0.001
Age, sex & BMI adjusted
IL-1b (pg/mL) 20.08 0.03 0.013 20.06 0.04 0.141 20.11 0.05 0.028 0.288
IL-6 (pg/mL) 0.04 0.03 0.128 0.02 0.04 0.625 0.09 0.04 0.042 0.387
TNF-a (pg/mL) 0.06 0.02 ,0.001 0.05 0.02 0.040 0.08 0.03 0.004 0.278
CRP (mg/L) 0.17 0.02 ,0.001 0.16 0.03 ,0.001 0.21 0.03 ,0.001 0.046
Fully adjusted**
IL-1b (pg/mL) 20.07 0.03 0.034 20.04 0.04 0.333 20.11 0.05 0.030 0.218
IL-6 (pg/mL) 0.05 0.03 0.107 0.04 0.04 0.324 0.07 0.05 0.110 0.399
TNF-a (pg/mL) 0.06 0.02 0.003 0.05 0.02 0.045 0.06 0.03 0.025 0.297
CRP (mg/L) 0.19 0.02 ,0.001 0.19 0.03 ,0.001 0.22 0.03 ,0.001 0.047
Fully adjusted excluding BMI
IL-1b (pg/mL) 20.07 0.03 0.027 20.03 0.04 0.445 20.12 0.05 0.012 0.418
IL-6 (pg/mL) 0.10 0.03 ,0.001 0.07 0.04 0.063 0.15 0.04 0.001 0.112
TNF-a(pg/mL) 0.08 0.02 ,0.001 0.06 0.02 0.006 0.10 0.03 ,0.001 0.118
CRP (mg/L) 0.35 0.02 ,0.001 0.29 0.03 ,0.001 0.44 0.03 ,0.001 ,0.001
*P-value for interaction between serum uric acid and sex. IL-1b= interleukin-1b; IL-6 = interleukin-6: TNF-a= tumour necrosis factor-alpha; CRP = ultrasensitive C-reactive
protein.
**Adjusted for age, sex, alcohol intake, smoking, BMI, GFR (calculated according to Modification in Diet in Renal Disease equation), diabetes, hypertension & use of
diuretic.
doi:10.1371/journal.pone.0019901.t005
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